Table 1.
Study | Sample size | Age (years)† | Female (%) | CKD stage* | DM (%) | CVD (%) | IMT (μm) | Outcome | Comparison | Effect estimate (95% CI) | Follow-up duration (months) |
---|---|---|---|---|---|---|---|---|---|---|---|
He et al. [15] | 128 | 56 | 54 | Hemodialysis | 13.3 | NA | NA | All-cause mortality |
|
|
24 |
Hinderliter et al. [16] | 198 | 61 | 47 | Non-hemodialysis | 26 | 42 | 1210 | CV events (cardiac death, myocardial infarction, coronary revascularization, stroke, heart failure and peripheral vascular disease) |
|
|
29 |
Yu et al. [17] | 145 | 55 | 45.5 | Hemodialysis | 11 | 13.7 | NA |
|
|
|
73 |
Karras et al. [18] | 439 | 60 | 26 | CKD Stage 3–5, not on dialysis | 27 | 28 | NA |
|
|
|
NA |
Nakayama et al. [19] | 133 | NA | 42 | Hemodialysis | 43 | 39 | NA |
|
|
|
49 |
Papagianni et al. [20] | 112 | 59 | 46.4 | Hemodialysis | NA | 34.8 | NA |
|
|
|
46 |
Zoungas et al. [25] | 207 | 57 | 32 | General CKD | NA | 72 | NA |
|
|
|
60 |
London et al. [21] | 78 | 54 | 30.7 | Hemodialysis | 8.9 | 0 | 800 ± 98 | All-cause mortality |
|
|
60 |
Kato et al. [22] | 219 | 58 | 34.2 | Hemodialysis | 16 | NA | NA |
|
|
|
60 |
Nishizawa et al. [23] | 438 | 60 | 40 | Hemodialysis | 30 | NA | 980 ± 430 | CV mortality |
|
|
30 |
Benedetto et al. [24] | 138 | 60 | 41 | Hemodialysis | 14 | 57 | NA |
|
|
|
30 |
DM, diabetes mellitus.